

S3 Table. Clinicopathological characteristics of 534 cases of TCGA KIRC cohort according to FPN and FBXL5 mRNA expression level

Variable	No. of cases (n=534)	FPN mRNA level			FBXL5 mRNA level		
		High (%) (n=267)	Low (%) (n=267)	p-value	High (%) (n=267)	Low (%) (n=267)	p-value
Age (yr)		60.3±11.9	61.0±12.4	0.501	61.1±12.2	60.2±12.1	0.398
Sex							
Female	188	100 (37.5)	88 (33.0)	0.277	112 (41.9)	76 (28.5)	0.001
Male	346	167 (62.5)	179 (67.0)		155 (58.1)	191 (71.5)	
Nuclear grade ^{a)}							
1 and 2	243	133 (50.4)	110 (42.0)	0.054	137 (51.9)	106 (40.5)	0.009
3 and 4	283	131 (49.6)	152 (58.0)		127 (48.1)	156 (59.5)	
Pathologic T stage							
pT1 and pT2	343	190 (71.2)	153 (57.3)	0.001	194 (72.7)	149 (55.8)	< 0.001
pT3	180	75 (28.1)	105 (39.3)		72 (27.0)	108 (40.4)	
pT4	11	2 (0.7)	9 (3.4)		1 (0.3)	10 (3.8)	
Recurrence/Metastasis ^{b)}							
Absent	309	172 (76.4)	137 (64.9)	0.008	180 (78.6)	129 (62.3)	< 0.001
Present	127	53 (23.6)	74 (35.1)		49 (21.4)	78 (33.7)	
Survival							
Alive	359	196 (73.4)	163 (61.0)	0.002	205 (76.8)	154 (57.7)	< 0.001
Expired	175	71 (26.6)	104 (39.0)		62 (23.2)	113 (42.3)	

FBXL5, F-Box and leucine rich repeat protein 5; FPN, ferroportin; KIRC, Kidney renal clear cell carcinoma; TCGA, The Cancer Genome

Atlas. ^{a)}Nuclear grade was available in 526 cases, ^{b)}Follow-up data for recurrence or metastasis was available in 436 patients.